Android app Apple app link

Johnson & Johnson (NYSE:JNJ) Gains FDA Fast Track For Nipocalimab In Treating Sjogren's Disease

By Yahoo! Finance   |   1 month ago
Johnson & Johnson (NYSE:JNJ) Gains FDA Fast Track For Nipocalimab In Treating Sjogren's Disease

Johnson & Johnson's recent 11% share price increase is driven by regulatory wins and positive clinical data. FDA's Fast Track Designation for nipocalimab and Health Canada's approval for LAZCLUZE contribute to a strengthened therapeutic portfolio.

Read More

Did you find this insightful?

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

To become a member, please download and purchase membership through our app.